SystImmune Inc. has announced the creation of its Clinical Science Advisory Committee, appointing Dr. Hope Rugo, M.D., Dr. Sara Tolaney, M.D., M.P.H, Dr. Pasi Jänne, M.D., Ph.D., MMSC.
Sanofi announced that the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976, as amended, applicable to Sanofi’s proposed acquisition of Provention Bio, Inc.
After the end of the quarter, we received very positive news in our BI-1206 project.
BioInvent International AB: Interim Report January-March 2023 Read More »
Alentis Therapeutics announced results from the multiple-ascending dose part of its first-in-human Phase 1 clinical study of ALE.F02 targeting Claudin-1.
AGC Biologics announced it has received the “Bioprocessing Excellence in Japan” award at the Asia-Pacific Bioprocessing Excellence Awards ceremony for the work and achievements at the AGC Biologics Chiba, Japan site.
AGC Biologics Received Bioprocessing Excellence Award in Japan Read More »
RemeGen Co., Ltd., a commercial-stage biotechnology company, is celebrating World Intellectual Property Day 2023 which falls on April 26, the theme of which mirrors the critical importance RemeGen places on intellectual property rights for its accelerated innovation and creativity.
RemeGen Celebrates World Intellectual Property Day 2023 Read More »
Sorrento Therapeutics, Inc. announced that, in connection with its ongoing chapter 11 case, the U.S. Bankruptcy Court for the Southern District of Texas entered an order extending the expiration of the restrictions on transfer on the shares of common stock of Scilex Holding Company that were distributed by Sorrento to its stockholders as a dividend
Epsilogen Ltd, a global leader in the development of novel immunoglobulin E antibodies to treat cancer, announced three new senior hires in what is a significant expansion of their management team.
Epsilogen announces significant expansion of management team with three new senior hires Read More »
Huma Therapeutics and UCB are partnering to offer a digital technology solution to help patients with the rare disease, Myasthenia gravis, better understand and manage their condition with the support of their clinician.
Nicox SA announced that studies highlighting nonclinical data on NCX 470 and NCX 1728 have been presented at the Association for Research in Vision and Ophthalmology Annual Meeting 2023 being held April 23-27, 2023 in New Orleans, LA, United States.
New Data on Two Nicox’s Assets, NCX 470 and NCX 1728, Presented at ARVO 2023 Read More »
